| XLS |
|
|
|
|
|
€ million |
Q1 – 2012 |
Q1 – 2011 |
|
Profit after tax |
176.6 |
344.2 |
|
Depreciation/amortization/impairment losses/write-ups |
342.7 |
353.0 |
|
Changes in inventories |
7.0 |
–62.7 |
|
Changes in trade accounts receivable |
–44.2 |
–30.6 |
|
Changes in trade accounts payable |
26.1 |
–109.8 |
|
Changes in provisions |
22.8 |
25.8 |
|
Changes in other assets and liabilities |
–52.2 |
–68.2 |
|
Neutralization of gain/loss on disposals of assets |
–10.1 |
–164.1 |
|
Other non-cash income and expenses |
3.2 |
–2.6 |
|
Net cash flows from operating activities |
471.9 |
284.9 |
|
|
|
|
|
Purchase of intangible assets |
–29.1 |
–9.3 |
|
Purchase of property, plant and equipment |
–50.7 |
–74.9 |
|
Acquisitions |
– |
– |
|
Investments in financial assets |
–5.6 |
–0.6 |
|
Disposal of non-current assets |
31.4 |
485.4 |
|
Purchase/sale of marketable securities |
1.7 |
–40.2 |
|
Changes in other financial assets |
370.2 |
–256.1 |
|
Net cash flows from investing activities |
318.0 |
104.3 |
|
|
|
|
|
Dividend payments |
–0.7 |
– |
|
Profit transfers to E. Merck KG and changes in reserves |
–69.0 |
–104.8 |
|
Changes in liabilities to E. Merck KG |
–10.0 |
–19.8 |
|
Repayment of bonds |
–500.0 |
– |
|
Changes in current and non-current financial liabilities |
–58.2 |
–22.8 |
|
Net cash flows from financing activities |
–637.9 |
–147.4 |
|
|
|
|
|
Changes in cash and cash equivalents |
152.0 |
241.8 |
|
Changes in cash and cash equivalents due to currency translation |
–3.0 |
–8.0 |
|
Cash and cash equivalents as of January 1 (Group balance sheet) |
937.8 |
943.7 |
|
Plus cash and cash equivalents previously in assets held for sale |
– |
1.2 |
|
Cash and cash equivalents as of March 31 |
1,086.8 |
1,178.7 |